Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Lymphoma, Large B-Cell, Diffuse 14Prostatic Neoplasms 12Burkitt Lymphoma 11Lymphoma, Follicular 9Lymphoma 6Prostatic Neoplasms, Castration-Resistant 5Neoplasms 4Lymphoma, Non-Hodgkin 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Lymphoproliferative Disorders 2Lymphoma, B-Cell 2Recurrence 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multi-centric Castleman's Disease 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Macular dystrophy, corneal type 1 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphadenopathy 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1

Interventions

Prednisone 5Docetaxel 4niraparib 2Abiraterone Acetate 2olaparib 1ibrutinib 1fludrocortisone acetate 1enzalutamide 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pluvicto 1Pioglitazone 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Prednisone × 30 days × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT07225946 2026-05-11

KLK2-PASenger

Janssen Research & Development, LLC

Phase 3 Recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡